Study of LM11A-31-BHS in Mild-moderate AD Patients

Phase 1/2 Completed 242 enrolled PharmatrophiX Inc. National Institute on Aging (NIA) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS

Timeline

Start: 2017-02-15
Primary completion: 2020-06-08
Completion: 2020-06-08

Publications

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Borjesson-Hanson A, Windisch M, Schmitz TW. p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial. Nat Med. 2024 Jun;30(6):1761-1770. doi: 10.1038/s41591-024-02977-w. Epub 2024 May 17.
Liu G, He M, Wu C, Lv P, Sun H, Wang H, Xin X, Liao H. Axonal injury mediated by neuronal p75NTR/TRAF6/JNK pathway contributes to cognitive impairment after repetitive mTBI. Exp Neurol. 2024 Feb;372:114618. doi: 10.1016/j.expneurol.2023.114618. Epub 2023 Nov 27.
Malik SC, Sozmen EG, Baeza-Raja B, Le Moan N, Akassoglou K, Schachtrup C. In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target. Trends Pharmacol Sci. 2021 Sep;42(9):772-788. doi: 10.1016/j.tips.2021.06.006. Epub 2021 Jul 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	LM11A-31	Small molecule	200 mg	Oral
Comparator	LM11A-31	Small molecule	400 mg	Oral

Indications

No indication recorded.